SCHEMBL30765644

SCHEMBL30765644

CSc1ncc(NCCCc2ccccc2)c(=O)n1CC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
ASPH Q12797 2/20 0.42
RIOX2 Q8IUF8 2/20 0.42
KDM8 Q8N371 2/20 0.42
ALDH1A1 P00352 1/20 0.42
F2 P00734 1/20 0.40
EGLN1 Q9GZT9 1/20 0.39
KDM6B O15054 2/20 0.39
KDM4C Q9H3R0 2/20 0.39
POLB P06746 2/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
SLC2A1 P11166 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
GRM2 Q14416 1/20 0.35
SIGMAR1 Q99720 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460591 0.94 KDM4E (0.43) KDM4EASPHRIOX2KDM8ALDH1A1
SCHEMBL30765612 0.88 KDM4E (0.44) KDM4EALDH1A1F2
SCHEMBL30765873 0.86 KDM4E (0.41) KDM4EASPHRIOX2KDM8ALDH1A1
SCHEMBL30765994 0.86 ELANE (0.46) KDM4EASPHRIOX2KDM8ALDH1A1
SCHEMBL30765606 0.85 MEN1 (0.44) KDM4EASPHRIOX2KDM8ALDH1A1
SCHEMBL30765457 0.83 ELANE (0.43) KDM4EASPHRIOX2KDM8ALDH1A1
SCHEMBL30765773 0.82 ELANE (0.41) KDM4EASPHRIOX2KDM8ALDH1A1
SCHEMBL23460649 0.80 ELANE (0.47) KDM4EASPHRIOX2KDM8ALDH1A1
SCHEMBL30765501 0.77 ELANE (0.44) KDM4EALDH1A1F2EGLN1NPC1
SCHEMBL30765833 0.77 JAK2 (0.38) KDM4EASPHRIOX2KDM8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed